Is Wockhardt a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Wockhardt Ltd is a below average quality company .

Is Wockhardt undervalued or overvalued?

The key valuation ratios of Wockhardt Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Wockhardt share price return in the past 10 years?

Wockhardt Ltd share price has appreciated 5.1% annually (CAGR) over the past ten years.

Is Wockhardt a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Wockhardt Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Wockhardt Ltd - Stock Valuation and Financial Performance

Name: Wockhardt
Brand: Wockhardt

BSE: 532300 | NSE: WOCKPHARMA | Pharmaceuticals & Drugs | Small Cap

Place order

Wockhardt Share Price

₹1,230.95 58.60 5.00%
as on 22-Nov'24 16:59

10 Year X-Ray of Wockhardt:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	11.3%	6.9%	-0.3%	-5.5%	-2.9%	-1.1%	-5.5%	-2%	-5.9%	-2.2%	-
Value Creation Index ⓘ	-0.2	-0.5	-1.0	-1.4	-1.2	-1.1	-1.4	-1.1	-1.4	-1.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	4,482	4,453	4,015	3,937	3,566	2,844	2,708	3,230	2,651	2,798	2,949
Sales YoY Gr.	-	-0.6%	-9.9%	-1.9%	-9.4%	-20.2%	-4.8%	19.3%	-17.9%	5.6%	-
Adj EPS ⓘ	39.2	21.8	-17.9	-37.1	-22.6	-14.9	-22	-8.6	-29.8	-27.3	-17.7
YoY Gr.	-	-44.3%	-182.1%	NA	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	282.2	312.4	275.1	234.5	220	219.8	280.5	266	231.8	217.3	270.5
Adj Net Profit ⓘ	468	261	-215	-445	-272	-179	-265	-124	-429	-418	-288
Cash Flow from Ops. ⓘ	355	71.6	-269	68.4	183	649	-287	413	153	219	-
Debt/CF from Ops. ⓘ	5.7	37.4	-15.4	54.8	18.4	5	-8.1	4.5	12.3	9.6	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-5.1%	-4.7%	1.1%	5.6%
Adj EPS ⓘ	-196.1%	NA	NA	NA
BVPSⓘ	-2.9%	-0.3%	-8.2%	-6.3%
Share Price	5.1%	39.3%	45.7%	258.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	12.8	7	-6	-14.4	-9.8	-6.7	-8.8	-3.4	-11.9	-12.5	-7.3
Op. Profit Mgn % ⓘ	18.5	11.4	0.7	-1.4	-0.4	3.4	-2.3	9.2	3.9	3.3	5.8
Net Profit Mgn % ⓘ	10.6	5.9	-6.1	-12.8	-8.3	-5.4	-9.7	-4.9	-18.5	-15.3	-9.8
Debt to Equity ⓘ	0.6	0.7	1.3	1.3	1.3	1.2	0.7	0.5	0.6	0.6	0.4
Working Cap Days ⓘ	192	223	242	233	255	320	180	161	188	198	123
Cash Conv. Cycle ⓘ	68	99	134	116	114	130	37	10	-7	15	-33

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.63

Return on Equity is Poor

Sales growth has been subdued in last 3 years 1.10%

Sales growth is not so good in last 4 quarters at 6.43%

Latest Financials - Wockhardt Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-14.2	-17.7
TTM Sales (₹ Cr.)	1,365	2,949
BVPS (₹.) ⓘ	170.2	270.5
Reserves (₹ Cr.) ⓘ	2,683	4,313
P/BV ⓘ	6.99	4.40
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	323.30 / 1334.55
All Time Low / High (₹)	62.20 / 1996.06
Market Cap (₹ Cr.)	19,334
Equity (₹ Cr.)	81.2
Face Value (₹)	5
Industry PE ⓘ	43.4

Management X-Ray of Wockhardt:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

47.84

52.77

56.08

65.46

69.08

64.38

74.51

52.90

37.47

33.64

* Pledged shares as % of Promoter's holding (%)

Valuation of Wockhardt

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Wockhardt

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	4,482	4,453	4,015	3,937	3,566	2,844	2,708	3,230	2,651	2,798
Operating Expenses ⓘ	3,772	3,959	4,002	3,992	3,604	2,746	2,771	2,932	2,550	2,759
Manufacturing Costs	349	366	290	213	247	206	227	267	229	249
Material Costs	1,487	1,614	1,662	1,798	1,636	1,203	1,135	1,267	1,111	1,165
Employee Cost	869	951	967	937	800	743	763	749	637	629
Other Costs ⓘ	1,067	1,028	1,084	1,045	921	593	646	649	573	716
Operating Profit ⓘ	709	494	13	-55	-38	98	-63	298	101	39
Operating Profit Margin (%)	15.8%	11.1%	0.3%	-1.4%	-1.1%	3.4%	-2.3%	9.2%	3.8%	1.4%
Other Income ⓘ	67	66	114	177	21	60	132	20	122	83
Interest ⓘ	55	129	225	255	265	276	249	299	302	305
Depreciation ⓘ	145	142	149	150	164	224	246	247	251	223
Exceptional Items ⓘ	0	0	0	-358	0	0	-142	-183	-294	-14
Profit Before Tax ⓘ	575	289	-247	-641	-447	-342	-568	-411	-624	-420
Tax ⓘ	163	38	-21	26	-135	-204	-271	-132	-3	52
Profit After Tax	413	252	-226	-667	-312	-138	-297	-279	-621	-472
PAT Margin (%)	9.2%	5.6%	-5.6%	-16.9%	-8.7%	-4.9%	-11.0%	-8.6%	-23.4%	-16.9%
Adjusted EPS (₹)	33.9	20.9	-16.3	-50.7	-16.2	-5.8	57.5	-16.9	-38.8	-30.1
Dividend Payout Ratio (%)	54%	0%	-56%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	3,669	3,746	3,300	2,815	2,643	2,642	3,348	3,831	3,338	3,346
Share Capital ⓘ	354	55	55	55	55	55	55	72	72	77
Reserves ⓘ	3,316	3,691	3,244	2,760	2,587	2,586	3,293	3,759	3,266	3,269
Minority Interest	144	465	382	346	330	386	383	353	308	303
Debt	1,533	2,471	3,853	2,610	2,453	2,145	1,569	1,389	1,554	1,723
Long Term Debt	1,185	1,921	3,190	2,173	1,891	1,241	503	355	224	891
Short Term Debt	348	550	663	437	562	904	1,066	1,034	1,330	832
Trade Payables	553	638	534	602	840	895	696	921	867	766
Others Liabilities ⓘ	1,606	656	780	1,605	1,305	1,682	1,380	1,176	1,008	932
Total Liabilities ⓘ	7,505	7,976	8,849	7,978	7,571	7,749	7,376	7,670	7,075	7,070
Fixed Assets
Gross Block	4,553	4,377	5,456	5,772	6,113	6,703	5,656	6,019	5,696	5,721
Accumulated Depreciation	2,430	1,568	2,684	2,884	3,055	3,201	2,313	2,557	2,654	2,840
Net Fixed Assetsⓘ	2,123	2,809	2,773	2,888	3,058	3,502	3,343	3,462	3,042	2,881
CWIP ⓘ	1,007	1,036	1,244	1,433	1,445	1,585	1,379	1,342	1,539	1,722
Investmentsⓘ	341	0	563	214	0	0	0	0	0	0
Inventories	1,021	1,102	1,108	856	819	716	799	769	658	640
Trade Receivables	741	1,111	1,034	962	1,274	1,243	918	918	797	618
Cash Equivalents	1,235	1,478	1,604	1,082	449	268	292	406	124	529
Others Assetsⓘ	1,037	439	524	544	525	435	645	773	915	680
Total Assets ⓘ	7,505	7,976	8,849	7,978	7,571	7,749	7,376	7,670	7,075	7,070

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	355	72	-269	68	183	649	-287	413	153	219
PBT ⓘ	575	289	-247	-641	-300	-197	916	-411	-624	-420
Adjustment ⓘ	286	262	303	449	445	483	-943	554	635	677
Changes in Working Capital ⓘ	-345	-396	-297	278	80	380	-143	367	153	-8
Tax Paid ⓘ	-161	-84	-28	-18	-41	-17	-117	-97	-11	-30
Cash Flow From Investing Activity ⓘ	-207	-818	-687	630	95	-156	1,470	-201	-125	-137
Capex	-431	-492	-409	-306	-270	-163	-69	-211	-130	-150
Net Investments	240	373	-520	440	213	0	0	0	0	0
Others ⓘ	-16	-699	242	496	151	8	1,539	10	5	13
Cash Flow From Financing Activityⓘ	-76	254	1,254	-769	-776	-680	-1,171	-71	-315	334
Net Proceeds from Shares ⓘ	0	86	0	0	0	0	0	748	0	468
Net Proceeds from Borrowing ⓘ	95	67	1,478	-306	-619	-601	-783	-737	-290	-293
Interest Paid ⓘ	-56	-88	-206	-233	-259	-248	-235	-190	-242	-197
Dividend Paid ⓘ	-245	0	-138	0	0	0	-1	-2	0	0
Others ⓘ	130	190	121	-231	101	169	-152	110	217	356
Net Cash Flow ⓘ	73	-492	298	-71	-499	-186	12	141	-287	416

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	12.49	7.07	-6.42	-21.81	-11.43	-5.22	-9.92	-7.77	-17.32	-14.12
ROCE (%)	11.25	6.87	-0.31	-5.47	-2.87	-1.11	-5.5	-1.96	-5.88	-2.15
Asset Turnover Ratio	0.64	0.58	0.48	0.47	0.46	0.37	0.61	0.68	0.58	0.51
PAT to CFO Conversion(x)	0.86	0.29	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	50	76	98	93	114	161	85	65	73	72
Inventory Days	82	87	100	91	86	99	60	56	61	66
Payable Days	136	135	129	115	161	263	256	233	294	256

Wockhardt Ltd Stock News

Wockhardt Ltd FAQs

What is the share price of Wockhardt?

Company share prices are keep on changing according to the market conditions. The closing price of Wockhardt on 22-Nov-2024 16:59 is ₹1,231.

What is the market cap of Wockhardt?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 22-Nov-2024 16:59 the market cap of Wockhardt stood at ₹19,334.2.

What is the P/E ratio of Wockhardt?

The latest P/E ratio of Wockhardt as of 22-Nov-2024 16:59 is 0.00.

What is the P/B ratio of Wockhardt?

The latest P/B ratio of Wockhardt as of 22-Nov-2024 16:59 is 6.99.

What is the 52-week high and low of Wockhardt?

The 52-week high of Wockhardt is ₹1,334.6 and the 52-week low is ₹323.3.

What is the TTM revenue of Wockhardt?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Wockhardt is ₹1,365 ( Cr.) .

About Wockhardt Ltd

Wockhardt Ltd. is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals. It is a true Indian Multi-National Company with a multi-ethnic workforce of many Wockhardt Associates from many different nationalities globally. It has many research centres and several manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. It is a business in transition. New and innovative business models are in motion to make the most of emerging opportunities. A new drive for growth today permeates every mind-set, process and techno-innovation within Wockhardt.

Business area of the company

The company is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.

Awards

2009

Outstanding National Citizen Award by National Citizens Guild.
Strathmore’s Who’s Who - Social Entrepreneur of the Year.

2010

AmeriCares India Spirit of Humanity Award.
USA BF Foundation of the Year Award.
HEF Award for ‘Outstanding contribution to the teaching community with special reference to Human Values.
Best Pharma CSR award at the Pharmaceutical Leadership Summit.

2011

IDF - CSR Award.

2012

Inclusive India Award under the Corporate category for ‘Best Social Work in the Realm of Primary Healthcare’.
IPE CSR Corporate Governance Award.

2013

Rajiv Gandhi Global Excellence Award.
Rajiv Gandhi Excellence Award.
Bharat Gaurav Award.
Asian CSR Leadership Awards.
CSR Excellence & Leadership Award.
Asia Peace Award.

2015

Best CSR Project in Healthcare for Mobile 1000 Medical vans - India CSR.
Best Community Development Award for Mobile 1000 - World CSR Congress.
CSR Professional of the Year - World CSR Congress.
Maharashtra Class Owners Association Meritorious Award for valuable contribution in the field of education.
Bronze Award for Table Calendar - A.B.C.I (Association of Business Communicators of India).
Social Entrepreneur of the Year 2015 - Pharma Leaders.
Swachh Bharat Samman - India CSR.
Best Environment Friendly Project for Bio-Toilets - Asian CSR Leadership Awards.

2016

CSR Leadership Award.
Lions CSR Precious Award.
Champion of WSIS Prize 2016 - World Summit on the Information Society.
Outstanding Leadership Award - Nurturing the Future Foundation.
Peace Leader of the Year 2016 - 7th India Leadership Conclave and Indian Affairs Business Leadership Awards 2016.
Best Service Award for Significant National Contribution - Institute of Technology & Science.
Asia Healthcare Excellence Award - CMO Asia.

2017

Excellence Award for Corporate Social Responsibility & Peace Mission - Indian Virtual University for Peace and Education (IVUP).
Global NGO Excellence Award for Excellence in Mother & Child Care - World CSR Day.
CSR Humanity Award’ by India CSR.
Lifetime Achievement Award from the National Institute of Cleanliness Education and Research (NICER).
Indian of the Year 2017 (Social Service) by ILC Power Brand.
The Rotary Peace Ambassador Award by Rotary.
CSR Impact Award by IndiaCSR.
Magnificient Man Choice Award with specialization in CEO CSR Excellence from Hopewill International Business Academy.

2018

Game Changer Award by The HR Club.
Sabarmati Festival Foundation Award for Outstanding Social Work from Sabarmati Festival Foundation.
Divyang Ratna Award 2018 by Disable Welfare Trust of India.

2019

Mumbai Heroes Award from Blossom Media Pvt Ltd at the Humanity First Conclave.
Inspiring Indian Award from Indian Ex Defence Service Employees Chamber of Commerce & Industries (IESECCI).
Award for Peace Mobilization from Poddar Foundation at the Insure your Mental Health Conference (Celebrating World Health Day).
Inspirational Indian of the Year at the The Mumbai Achievers Awards 2019 by Mumbai Halchal.
Bharat Shree Award 2019.
Rotary Award from Rotary Club of Mumbai Khar.
H F F Excellence Award from Humanity First Foundation.

2020

‘For the Sake of Honour’ Award from Rotary.
Excellence in Human Welfare Award from Charity with a Twist, Nargis Dutt Foundation, ECOMO.

Milestones

2010

Wockhardt receives US FDA approval for antibacterial Levofloxacin.
Wockhardt launches Prostate drug Flomax in the United States on Day-1.
Wockhardt receives US FDA approval for the generic version of Toprol XL, a cardiac drug.

2011

Wockhardt launches generic version of Protonix tablets in the US.
Wockhardt receives US FDA approval for generic version of Effexor XR capsules.
Wockhardt launches three new products in three weeks, in the United States.
Wockhardt receives tentative US FDA approval for generic version of Patanol ophthalmic solution.

2012

Wockhardt launches generic version of anti-ulcer drug Prevacid.
Wockhardt receives US FDA approval for generic version of Parkinsonism drug Requip XL.
Wockhardt receives tentative US FDA approval for generic version of anti-psychotic drug Geodon.
Wockhardt receives US FDA approval for generic version of Parkinson’s drug Comtan.

2013

Wockhardt receives the 'Best Enterprise' award from the Europe Business Assembly.
Wockhardt launches generic version of anti-convulsant drug Lamictal XR.

2014

Wockhardt’s drug discovery gets a boost with fast track approval by USFDA.

2015

Wockhardt Receives ANDA Approval for pain medication Oxycodone liquid.
Wockhardt receives Qualified Infectious Disease Product (QIDP) designation for its new Drug WCK 4873 from U.S. FDA -US FDA grants breakthrough (QIDP) drug discovery status to the New Antibiotic of Wockhardt.

2018

Wockhardt sets up its first manufacturing and R&D unit in Middle East.

2019

Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for 50mg injection of Decitabine, which is used to treat certain forms of cancer.
Wockhardt has received approval from the United States Food & Drug Administration (US FDA) for an ANDA for 100mg and 400mg tablets of Imatinib Mesylate, which is used to treat many kinds of cancers and tumors.

2020

Wockhardt has entered into an agreement with the UK Government to fill finish COVID-19 vaccines.
Wockhardt has received approval from Indian drug regulator -- Drug Controller General of India (DCGI) for 2 new antibiotics, EMROK (IV) and EMROK O (Oral), which is used to treat acute bacterial skin and skin structure Infections including diabetic foot infections and concurrent bacteraemia based on the Phase 3 study involving 500 patients in 40 centres across India.
Wockhardt has received approval for the transfer of business comprising 62 products and line extensions along with related business assets and liabilities, contracts, permits, intellectual properties, employees, marketing, sales and distribution of the same in the Domestic Branded Division in India, Nepal, Bhutan, Sri Lanka and Maldives; and manufacturing facility in Baddi, Himachal Pradesh, India, where some of the said pharmaceutical products which are being transferred are manufactured and together referred to as the Business Undertaking by way of a slump sale to Dr. Reddy's Laboratories for Rs 1,850 crore as per the terms and conditions specified in the Business Transfer Agreement (BTA).
Wockhardt announced COVID-19 vaccine partnership with UK Government.